On Oct. 15, 2020, Ionis Pharmaceuticals announced that IONIS-PKK-LRx was being evaluated in an investigator-initiated Phase 2 clinical study to determine its effectiveness in reducing the severity of respiratory complications in patients with COVID-19. The trial at the Hospital do Coracao, Sao Paulo, Brazil will enroll up to 110 patients at 25 hospitals.

Ionis provided IONIS-PKK-LRx and funding to the Brazilian Research for Intensive Care Network (BRICNet) to support the study.